OXFORD, England, April 26, 2012 /PRNewswire/ --
Europe's premier biotech conference continues to grow and see increased international participation
OBN, the not-for-profit business network which provides comprehensive support for bioscience businesses in the Oxford and South-East England biocluster and beyond, today announced the results of the sixth annual BioTrinity Biopartnering and Investment Conference. Held from April 24 - 26 at Newbury Racecourse, UK, BioTrinity is now firmly established as the largest UK bioindustry event and one of the premier events in Europe. The conference has now been Europe's fastest growing early-stage investment and partnering event for four years running.
The 2012 conference welcomed 800 delegates from over 480 companies from 26 countries across Europe, Asia and North America. 70 investment firms that specialise in funding emerging biotechnology and life science companies participated as did 20 pharmaceutical companies including all of the global top 10. This year saw more than 1925 one-to-one partnering meetings scheduled. This was up from 1,700 in 2011, continuing a growth trend from 500 meetings in 2008.
The increasing international profile of BioTrinity was highlighted by the make-up of the panel discussions with more than 60% of participants being drawn from outside the UK and from the US, Europe and Asia.
"BioTrinity continues to go from strength to strength and is now clearly one of the "must attend" events for the sector not only in the UK but in Europe and increasingly internationally," said Jon Rees, CEO, OBN. "Not only have we continued to grow but we are attracting ever more senior participants from across the industry, from regulatory and government bodies and particularly from the pharma companies eager to partner with the highly innovative companies we showcase."
Denise Goode, Executive Business Development Director, AstraZeneca, said: "BioTrinity is one of the key e
Copyright©2010 PR Newswire.
All rights reserved